Ascendis Pharma A/S
ASND
$223.82
-$3.59-1.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 38.04% | 44.66% | 44.58% | 32.53% | 21.33% |
| Total Depreciation and Amortization | 4.03% | -3.05% | -4.24% | -6.68% | -6.36% |
| Total Amortization of Deferred Charges | 14.58% | -4.27% | -4.27% | -4.27% | -4.27% |
| Total Other Non-Cash Items | 27.46% | 17.96% | -54.51% | -48.19% | 68.10% |
| Change in Net Operating Assets | 169.49% | -320.22% | 76.59% | 102.78% | -4.59% |
| Cash from Operations | 119.51% | 59.89% | 50.23% | 48.59% | 34.58% |
| Capital Expenditure | -525.89% | -473.59% | -319.64% | -22.16% | 41.49% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | 1,742.34% | 1,742.34% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.01% | -100.00% | -100.00% | -97.43% |
| Cash from Investing | -229.67% | -140.82% | -116.66% | -101.16% | -97.58% |
| Total Debt Issued | -- | -100.00% | -1.54% | -1.54% | -1.54% |
| Total Debt Repaid | -93.21% | -62.03% | -30.60% | -9.28% | -8.88% |
| Issuance of Common Stock | -74.42% | -70.62% | 1,058.78% | 1,024.07% | 3,209.62% |
| Repurchase of Common Stock | -- | -1,488.96% | -1,488.96% | -1,488.96% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -90.92% | -92.84% | 175.33% | 168.79% | 233.57% |
| Foreign Exchange rate Adjustments | -214.96% | 52.28% | -349.08% | 118.57% | 481.38% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -62.18% | -142.97% | 279.51% | 213.57% | 427.56% |